Bristol-Myers Squibb Co. Earnings: What's Next for the Drugmaker?

Bristol-Myers Squibb stock has hit decade highs lately, with promising drug candidates inspiring investors to greater confidence. But will Bristol-Myers Squibb earnings follow suit? Find out here.

Jan 23, 2014 at 7:00PM

Bristol-Myers Squibb (NYSE:BMY) will release its quarterly report on Friday, and the stock has already built in strong expectations about the drug developer's future, rising to their best levels since the early 2000s. Yet even though the company has worked to focus on its most lucrative potential treatment areas, Bristol-Myers will still have to contend with Merck (NYSE:MRK), Gilead Sciences (NASDAQ:GILD), and other pharma giants in developing blockbuster drugs that can outcompete those of its rivals.

Bristol-Myers Squibb has done a great job over the past year in finding growth opportunities, with promising work in diabetes and other high-profile areas. But more recently, the company has looked at narrowing in on specific categories of drugs, including cancer treatments and immunotherapy. That transformation could help Bristol-Myers grow earnings even faster, but it still leaves the company open to plenty of competition. Let's take an early look at what's been happening with Bristol-Myers Squibb over the past quarter and what we're likely to see in its report.

Stats on Bristol-Myers Squibb

Analyst EPS Estimate


Change From Year-Ago EPS


Revenue Estimate

$4.30 billion

Change From Year-Ago Revenue


Earnings Beats in Past 4 Quarters


Source: Yahoo! Finance.

Can Bristol-Myers earnings turn back upward?
In recent months, analysts have gotten nervous about the long-term potential for Bristol-Myers Squibb earnings, reducing their full-year 2014 projections by $0.17 per share. That hasn't stopped the stock's rise, though, with gains of 11% since mid-October.

Bristol-Myers Squibb's third-quarter earnings report was reasonably strong, with sales climbing 9% despite the ongoing impact of the loss of patent protection on former blockbuster drug Plavix. Bristol-Myers has seen success from some of its newer drugs, with skin-cancer treatment Yervoy's sales climbing 33% during the quarter. Moreover, international growth has been solid, with sales up 18% internationally despite pressure from a wide-ranging Chinese probe of several pharmaceutical companies that has had a big impact on sales throughout the industry.


Source:, Flickr.

But the real driver for Bristol-Myers has been promising drug results and strategic moves. In late October, the company said that its nivolumab treatment for non-small cell lung cancer produced impressive survival results, encouraging an analyst upgrade of the stock. Moreover, Bristol-Myers became the first company to submit an all-oral hepatitis C treatment regimen for approval in Japan, following phase 3 data supporting the combination of its daclatasvir and asunaprevir drugs. In light of Gilead's lead in the hepatitis C space with its Sovaldi all-oral treatment, Bristol-Myers' victory in Japan was substantial, and it's working with Merck on a potential new combination therapy as well.

Bristol-Myers has made a huge strategic bet, though, with the sale last month of its stake in its diabetes treatment prospects to AstraZeneca (NYSE:AZN). The move will allow Bristol-Myers to focus more on cancer drugs as well as its antiviral immunotherapies and some specialty drugs, but it ups the ante in forcing the company to fend off its competitors in those areas in order to succeed. Still, given the highly competitive diabetes market, Bristol-Myers might be better able to thrive in its remaining business areas without having to deal with the distraction of the highly dynamic diabetes-treatment area, where the FDA has been increasingly stringent in requiring costly trials.

In the Bristol-Myers earnings report, watch for the company to give a more detailed picture of its strategy after divesting its diabetes business. With more resources to dedicate to its remaining focus areas, Bristol-Myers Squibb needs to establish its ability to produce growth from its best prospects now and in the future.

Another way to profit from promising treatments
The best way to play the pharma and biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Click here to add Bristol-Myers Squibb to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.

Fool contributor Dan Caplinger has no position in any stocks mentioned. You can follow him on Twitter @DanCaplinger. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers